Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 35,000 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $7.00, for a total transaction of $245,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Tuesday, November 14th, Clay Thorp sold 15,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.02, for a total transaction of $105,300.00.
  • On Thursday, October 5th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.57, for a total transaction of $299,950.00.
  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total transaction of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.49, for a total transaction of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total transaction of $184,240.00.

Clearside Biomedical, Inc. (CLSD) traded up $0.02 during trading on Thursday, reaching $6.96. 100,131 shares of the company’s stock traded hands, compared to its average volume of 154,255. The company has a current ratio of 4.57, a quick ratio of 4.57 and a debt-to-equity ratio of 0.15. Clearside Biomedical, Inc. has a 52-week low of $5.44 and a 52-week high of $24.73.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.17). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.01 million. Clearside Biomedical had a negative net margin of 17,684.07% and a negative return on equity of 90.72%. equities analysts forecast that Clearside Biomedical, Inc. will post -2.25 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 35,000 Shares of Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/16/insider-selling-clearside-biomedical-inc-clsd-director-sells-35000-shares-of-stock.html.

Several large investors have recently made changes to their positions in the business. Nationwide Fund Advisors raised its position in Clearside Biomedical by 118.3% in the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after acquiring an additional 6,343 shares during the period. Citadel Advisors LLC acquired a new stake in Clearside Biomedical during the second quarter valued at approximately $117,000. Parametric Portfolio Associates LLC acquired a new stake in Clearside Biomedical during the second quarter valued at approximately $122,000. Wells Fargo & Company MN boosted its holdings in Clearside Biomedical by 325.0% during the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock valued at $133,000 after purchasing an additional 12,800 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Clearside Biomedical by 4.0% in the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock valued at $135,000 after acquiring an additional 563 shares during the last quarter. Hedge funds and other institutional investors own 52.55% of the company’s stock.

CLSD has been the topic of several analyst reports. Zacks Investment Research cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company reaffirmed a “buy” rating on shares of Clearside Biomedical in a report on Monday, August 7th. TheStreet cut shares of Clearside Biomedical from a “c-” rating to a “d” rating in a report on Friday, August 11th. Finally, ValuEngine cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $18.33.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Stock Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related stocks with our FREE daily email newsletter.